Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
में बचाया:
| मुख्य लेखकों: | , |
|---|---|
| स्वरूप: | पुस्तक |
| प्रकाशित: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| विषय: | |
| ऑनलाइन पहुंच: | Connect to this object online. |
| टैग: |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|
इंटरनेट
Connect to this object online.3rd Floor Main Library
| बोधानक: |
A1234.567 |
|---|---|
| प्रति 1 | उपलब्ध |